Optimization of patient selection for EGFR-TKIs in advanced non-small cell lung cancer by combined analysis of MET, EGFR, KRAS, and PIK3CA mutations.

7562 Background: Specific EGFR tyrosine Kinase inhibitors (TKIs) have been developed and used for the treatment of advanced NSCLC. Somatic activating mutations of EGFR gene and some clinical and pa...